LONDON and SOUTH SAN FRANCISCO, Calif., May 10, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration ...

Ellipta inhaler sits cold and matte on the stainless tray in a Bronx pulmonary clinic, its oval body small enough to disappear in a patient’s palm as respiratory therapist Maria López clicks open the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) ...

DUBLIN--(BUSINESS WIRE)--The "Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol ...

Dublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The "Global BREO Ellipta Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The global BREO ellipta drugs ...

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in ...

Trelegy Ellipta is a combination of three molecules in a single inhaler. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday approved sales of ...

Credit: Getty Images. The FDA has expanded the approval of Breo Ellipta to include maintenance treatment of asthma in children 5 to 17 years of age. The Food and Drug Administration (FDA) has expanded ...

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily ...